Posted By: nmbr1stckpckr “Wasn't Incelldx res
Post# of 148110
(Total Views: 632)
Posted On: 12/10/2020 5:12:25 PM
Posted By: nmbr1stckpckr
“Wasn't Incelldx responsible for measuring CCR5 receptacle occupancy for the HIV trials? Nader said FDA said that the method used to do so incorrect and the Company is working to fix this.”
NP once attempted to blame Incelldx for the RO data issue, but he hasn’t since. We’ve debunked this specific claim over and over. Incelldx only ran RO tests for the last 1/3 of the mono trial patients AND the RO test was PRed by CYDY in July or 2019 as being, “a significant milestone that may further increase the monotherapy response rate.” Additionally, after this PR, CYDY had meetings with the FDA to discuss the monotherapy tria, which would’ve included the RO test. Lastly, Dr. BP tweeted that the Incelldx RO test is perfect and that Pfizer is currently using a near identical test for their CCR5 drug trials. In fact, Incelldx has the RO data from the last 1/3 of the mono patients and Dr. BP has described that data as “amazing.”
“Wasn't Incelldx responsible for measuring CCR5 receptacle occupancy for the HIV trials? Nader said FDA said that the method used to do so incorrect and the Company is working to fix this.”
NP once attempted to blame Incelldx for the RO data issue, but he hasn’t since. We’ve debunked this specific claim over and over. Incelldx only ran RO tests for the last 1/3 of the mono trial patients AND the RO test was PRed by CYDY in July or 2019 as being, “a significant milestone that may further increase the monotherapy response rate.” Additionally, after this PR, CYDY had meetings with the FDA to discuss the monotherapy tria, which would’ve included the RO test. Lastly, Dr. BP tweeted that the Incelldx RO test is perfect and that Pfizer is currently using a near identical test for their CCR5 drug trials. In fact, Incelldx has the RO data from the last 1/3 of the mono patients and Dr. BP has described that data as “amazing.”
(7)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼